Meeting to commence at 10.30 am on Wednesday, 11th December 2019 in the Copthorne Hotel Cardiff, Culverhouse Cross, Cardiff CF5 6DH

AGENDA

1. Welcome and introduction

2. Apologies

3. Declarations of interest

4. Minutes of previous meeting 1/AWMSG/1219

5. Chairman's report (verbal update)

6. National Prescribing Indicators 2019-20
   - Analysis of Prescribing Data to June 2019 2/AWMSG/1219

7. Feedback from the AWPAG meeting held 18th September 2019 3/AWMSG/1219

8. Identifying and delivering the key priorities for AWMSG 4/AWMSG/1219

To protect commercial confidentiality the following appraisals will be held in private

9. Appraisal 1: Full Submission (WPAS)
   Glycerol phenylbutyrate (Ravicti®) adjunctive therapy for chronic management of patients with urea cycle disorders including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g. essential amino acids, arginine, citrulline, protein-free calorie supplements) 5/AWMSG/1219

10. Appraisal 2: Full Submission (WPAS)
    Fampridine (FAMPYRA®) for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4–7) 6/AWMSG/1219

The meeting will open to the public for the announcement of the appraisal recommendations

11. Any other business

12. Date of next meeting – Tuesday, 11th February 2020 in Cardiff